Home
About
Overview
Sharing Data
ORCID
Help
History (58)
Medical therapy for ulcerative colitis 2004.
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.
Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease.
Factoring in growth factors for treatment of inflammatory bowel disease.
See All 58 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Factoring in growth factors for treatment of inflammatory bowel disease.
Factoring in growth factors for treatment of inflammatory bowel disease. Curr Gastroenterol Rep. 2003 Dec; 5(6):485.
View in:
PubMed
authors with profiles
Stephen B. Hanauer